{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:13Z","timestamp":1792014253796,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medical Research Future Fund","award":["MRF2012410"],"award-info":[{"award-number":["MRF2012410"]}],"id":[{"id":"https:\/\/ror.org\/0513v5k17","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100022869","name":"Royal Australian and New Zealand College of Psychiatrists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227515\/Z\/23\/Z"],"award-info":[{"award-number":["227515\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Melbourne","id":[{"id":"https:\/\/ror.org\/01ej9dk98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40263-026-01326-4","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:53:54Z","timestamp":1786110834000},"page":"1527-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-4280","authenticated-orcid":false,"given":"Chiranth","family":"Bhagavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berlowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Issak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Zaloumis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Mayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orwa","family":"Dandash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1326_CR1","doi-asserted-by":"publisher","unstructured":"van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci Biobehav Rev. 2022. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104793.","DOI":"10.1016\/j.neubiorev.2022.104793"},{"key":"1326_CR2","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25:1434\u201352. https:\/\/doi.org\/10.1177\/0269881110382466.","journal-title":"J Psychopharmacol"},{"key":"1326_CR3","doi-asserted-by":"publisher","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan E V., Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022.","DOI":"10.1016\/j.celrep.2018.05.022"},{"key":"1326_CR4","doi-asserted-by":"publisher","unstructured":"Berkovitch L, Fauvel B, Preller KH, Gaillard R. Neurocognitive effects of psilocybin: a systematic and comprehensive review of neuroimaging studies in humans. Neurosci Biobehav Rev. 2025. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106239.","DOI":"10.1016\/j.neubiorev.2025.106239"},{"key":"1326_CR5","doi-asserted-by":"publisher","unstructured":"Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021:101\u201318. https:\/\/doi.org\/10.1111\/acps.13249.","DOI":"10.1111\/acps.13249"},{"key":"1326_CR6","doi-asserted-by":"publisher","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316\u201344. https:\/\/doi.org\/10.1124\/pr.118.017160.","DOI":"10.1124\/pr.118.017160"},{"key":"1326_CR7","first-page":"157","volume-title":"Handb clin neurol","author":"A Hallemans","year":"2020","unstructured":"Hallemans A, Verbeque E, Van de Walle P. Motor functions. In: Handb clin neurol. Elsevier; 2020. p. 157\u201370."},{"key":"1326_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"key":"1326_CR9","doi-asserted-by":"crossref","unstructured":"Weber ET, Andrade R. Htr2a gene and 5-HT2A receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci. 2010;4:36.","DOI":"10.3389\/fnins.2010.00036"},{"key":"1326_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0306-4522(87)90327-7","volume":"21","author":"A Pazos","year":"1987","unstructured":"Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain\u2014IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987;21:123\u201339.","journal-title":"Neuroscience"},{"key":"1326_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/syn.1106","volume":"42","author":"SL Eastwood","year":"2001","unstructured":"Eastwood SL, Burnet PWJ, Gittins R, Baker K, Harrison PJ. Expression of serotonin 5-HT2A receptors in the human cerebellum and alterations in schizophrenia. Synapse. 2001;42:104\u201314.","journal-title":"Synapse"},{"key":"1326_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","volume":"50","author":"MK Madsen","year":"2021","unstructured":"Madsen MK, Stenb\u00e6k DS, Arvidsson A, Armand S, Marstrand-Joergensen MR, Johansen SS, et al. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur Neuropsychopharmacol. 2021;50:121\u201332. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.06.001.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1326_CR13","doi-asserted-by":"publisher","unstructured":"Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, et al. A qualitative analysis of the psychedelic mushroom come-up and come-down. NPJ Mental Health Res. 2025;4. https:\/\/doi.org\/10.1038\/s44184-024-00095-6.","DOI":"10.1038\/s44184-024-00095-6"},{"key":"1326_CR14","doi-asserted-by":"publisher","unstructured":"Barnett BS, Mauney EE, King IV F. Psychedelic-assisted therapy: an overview for the internist. Cleve Clin J Med. 2025;92:171\u201380. https:\/\/doi.org\/10.3949\/ccjm.92a.24032.","DOI":"10.3949\/ccjm.92a.24032"},{"key":"1326_CR15","doi-asserted-by":"publisher","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry; 2022. https:\/\/doi.org\/10.3389\/fpsyt.2022.1040217.","DOI":"10.3389\/fpsyt.2022.1040217"},{"key":"1326_CR16","doi-asserted-by":"publisher","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177:391\u2013410. https:\/\/doi.org\/10.1176\/APPI.AJP.2019.19010035.","DOI":"10.1176\/APPI.AJP.2019.19010035"},{"key":"1326_CR17","doi-asserted-by":"publisher","unstructured":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology. 2018;235:2915\u201327. https:\/\/doi.org\/10.1007\/S00213-018-4981-X.","DOI":"10.1007\/S00213-018-4981-X"},{"key":"1326_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/ijnp\/pyx011","volume":"20","author":"A Bryson","year":"2017","unstructured":"Bryson A, Carter O, Norman T, Kanaan R. 5-HT2A agonists: a novel therapy for functional neurological disorders? Int J Neuropsychopharmacol. 2017;20:422\u20137.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1326_CR19","doi-asserted-by":"publisher","unstructured":"Yang Y, Wang Y, Wang X. Harnessing psychedelics for stroke recovery: therapeutic potential and mechanisms. Brain. 2025:1862\u20135. https:\/\/doi.org\/10.1093\/brain\/awaf093.","DOI":"10.1093\/brain\/awaf093"},{"key":"1326_CR20","doi-asserted-by":"publisher","unstructured":"Allen J, Dames SS, Foldi CJ, Shultz SR. Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential. Mol Psychiatry. Springer Nature; 2024. https:\/\/doi.org\/10.1038\/s41380-023-02360-0.","DOI":"10.1038\/s41380-023-02360-0"},{"key":"1326_CR21","doi-asserted-by":"publisher","unstructured":"Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K, et al. Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol. Wellcome Open Res. 2024;9:401. https:\/\/doi.org\/10.12688\/wellcomeopenres.22543.1.","DOI":"10.12688\/wellcomeopenres.22543.1"},{"key":"1326_CR22","doi-asserted-by":"publisher","unstructured":"Bradley ER, Sakai K, Fernandes-Osterhold G, Szigeti B, Ludwig C, Ostrem JL, et al. Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50:1200\u20139. https:\/\/doi.org\/10.1038\/s41386-025-02097-0.","DOI":"10.1038\/s41386-025-02097-0"},{"key":"1326_CR23","doi-asserted-by":"publisher","unstructured":"Bhagavan C, Bryson A, Carter O, Nielsen G, Berlowitz D, Issak S, et al. Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study. Acta Neuropsychiatr. 2025;38:1\u201340. https:\/\/doi.org\/10.1017\/neu.2025.10042.","DOI":"10.1017\/neu.2025.10042"},{"key":"1326_CR24","doi-asserted-by":"publisher","unstructured":"Bhagavan C, Carter O, Bryson A, Dandash O, Kanaan R. Psychedelics in functional disorders: a scoping review. Prog Neuropsychopharmacol Biol Psychiatry. 2026;145. https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111642.","DOI":"10.1016\/j.pnpbp.2026.111642"},{"key":"1326_CR25","doi-asserted-by":"publisher","unstructured":"Butler M, Seynaeve M, Nicholson TR, Pick S, Kanaan RA, Lees A, et al. Psychedelic treatment of functional neurological disorder: a systematic review. Ther Adv Psychopharmacol. 2020. https:\/\/doi.org\/10.1177\/2045125320912125.","DOI":"10.1177\/2045125320912125"},{"key":"1326_CR26","doi-asserted-by":"publisher","unstructured":"Perez DL, Edwards MJ, Nielsen G, Kozlowska K, Hallett M, Curt LaFrance Jr W. A decade of progress in motor functional neurological disorder: continuing the momentum. J Neurol Neurosurg Psychiatry. 2021;92:668-677. https:\/\/doi.org\/10.1136\/jnnp-2020-323953.","DOI":"10.1136\/jnnp-2020-323953"},{"key":"1326_CR27","doi-asserted-by":"publisher","unstructured":"Maier M, Ballester BR, Verschure PFMJ. Principles of neurorehabilitation after stroke based on motor learning and brain plasticity mechanisms. Front Syst Neurosci. 2019;13:74. https:\/\/doi.org\/10.3389\/FNSYS.2019.00074.","DOI":"10.3389\/FNSYS.2019.00074"},{"key":"1326_CR28","doi-asserted-by":"publisher","unstructured":"Hassett L. Physiotherapy management of moderate-to-severe traumatic brain injury. J Physiother. 2023;69:141\u20137. https:\/\/doi.org\/10.1016\/J.JPHYS.2023.05.015.","DOI":"10.1016\/J.JPHYS.2023.05.015"},{"key":"1326_CR29","doi-asserted-by":"publisher","unstructured":"Dromerick AW, Geed S, Barth J, Brady K, Giannetti ML, Mitchell A, et al. Critical Period after Stroke Study (CPASS): a phase II clinical trial testing an optimal time for motor recovery after stroke in humans. Proc Natl Acad Sci USA. 2021;118:e2026676118. https:\/\/doi.org\/10.1073\/PNAS.2026676118\/-\/DCSUPPLEMENTAL.","DOI":"10.1073\/PNAS.2026676118\/-\/DCSUPPLEMENTAL"},{"key":"1326_CR30","doi-asserted-by":"publisher","unstructured":"Jolliffe L, Lannin NA, Cadilhac DA, Hoffmann T. Systematic review of clinical practice guidelines to identify recommendations for rehabilitation after stroke and other acquired brain injuries. BMJ Open. 2018;8. https:\/\/doi.org\/10.1136\/bmjopen-2017-018791.","DOI":"10.1136\/bmjopen-2017-018791"},{"key":"1326_CR31","doi-asserted-by":"publisher","unstructured":"Bhagavan C, Kanaan R, Carter O, Nielsen G, Berlowitz D, Issak S, et al. Psilocybin and motor function: a triple-blind, dose-finding study in healthy participants. Psych Res Clin Pract. 2024;6:164\u2013175. https:\/\/doi.org\/10.1176\/appi.prcp.20240047.","DOI":"10.1176\/appi.prcp.20240047"},{"key":"1326_CR32","doi-asserted-by":"publisher","unstructured":"Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME. Safety pharmacology of acute psilocybin administration in healthy participants. Neurosci Appl. 2024;3. https:\/\/doi.org\/10.1016\/j.nsa.2024.104060.","DOI":"10.1016\/j.nsa.2024.104060"},{"key":"1326_CR33","doi-asserted-by":"publisher","unstructured":"Passie T, Guss J, Kr\u00e4henmann R. Lower-dose psycholytic therapy\u2014a neglected approach. Front Psychiatry. 2022. https:\/\/doi.org\/10.3389\/fpsyt.2022.1020505.","DOI":"10.3389\/fpsyt.2022.1020505"},{"key":"1326_CR34","doi-asserted-by":"publisher","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.30214.","DOI":"10.7759\/cureus.30214"},{"key":"1326_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649\u201365. https:\/\/doi.org\/10.1007\/s00213-011-2358-5.","journal-title":"Psychopharmacology"},{"key":"1326_CR36","doi-asserted-by":"publisher","unstructured":"Meshkat S, Al-Shamali H, Perivolaris A, Tullu T, Zeifman RJ, Zhang Y, et al. Pharmacokinetics of psilocybin: a systematic review. Pharmaceutics. 2025;17:411. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17040411\/S1.","DOI":"10.3390\/PHARMACEUTICS17040411\/S1"},{"key":"1326_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"1326_CR38","doi-asserted-by":"crossref","unstructured":"Cheng AC, Duda SN, McGuffin K, McEver M, Taylor R, Rezniczek GA, et al. Supporting rapid innovation in research data capture and management: the REDCap external module framework. J Am Med Inform Assoc. 2025;32:1149\u201356.","DOI":"10.1093\/jamia\/ocaf073"},{"key":"1326_CR39","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"1326_CR40","unstructured":"Stevens L, Kennedy N, Taylor RJ, Lewis A, Harrell FE, Shotwell MS, et al. A Redcap advanced randomization module to meet the needs of modern trials. Available at SSRN 5261054."},{"key":"1326_CR41","doi-asserted-by":"publisher","unstructured":"Nielsen G, Holt K. Physio4FMD: a randomised controlled trial of specialist physiotherapy for functional motor disorder. Trial Materials. 2024. https:\/\/doi.org\/10.24376\/rd.sgul.c.7172766.v1.","DOI":"10.24376\/rd.sgul.c.7172766.v1"},{"key":"1326_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-63","author":"NA de Morton","year":"2008","unstructured":"de Morton NA, Davidson M, Keating JL. The de Morton mobility index (DEMMI): an essential health index for an ageing world. Health Qual Life Outcomes. 2008. https:\/\/doi.org\/10.1186\/1477-7525-6-63.","journal-title":"Health Qual Life Outcomes"},{"key":"1326_CR43","doi-asserted-by":"crossref","unstructured":"Nielsen G, Ricciardi L, Meppelink AM, Holt K, Teodoro T, Edwards M. A simplified version of the psychogenic movement disorders rating scale: the simplified functional movement disorders rating scale (S\u2010FMDRS). Mov Disord Clin Pract. 2017;4:710\u20136.","DOI":"10.1002\/mdc3.12475"},{"key":"1326_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1545968307305353","volume":"22","author":"N Yozbatiran","year":"2008","unstructured":"Yozbatiran N, Der-Yeghiaian L, Cramer SC. A standardized approach to performing the action research arm test. Neurorehabil Neural Repair. 2008;22:78\u201390. https:\/\/doi.org\/10.1177\/1545968307305353.","journal-title":"Neurorehabil Neural Repair"},{"key":"1326_CR45","doi-asserted-by":"crossref","unstructured":"Mathiowetz V, Volland G, Kashman N, Weber K. Adult norms for the Box and Block Test of manual dexterity. Am J Occup Ther. 1985;39:386\u201391.","DOI":"10.5014\/ajot.39.6.386"},{"key":"1326_CR46","doi-asserted-by":"publisher","unstructured":"Jaeger J. Digit symbol substitution test. J Clin Psychopharmacol. 2018;38:513\u20139. https:\/\/doi.org\/10.1097\/JCP.0000000000000941.","DOI":"10.1097\/JCP.0000000000000941"},{"key":"1326_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2466\/PMS.108.3.717-720","volume":"108","author":"JT Eckner","year":"2009","unstructured":"Eckner JT, Whitacre RD, Kirsch NL, Richardson JK. Evaluating a clinical measure of reaction time: an observational study. Percept Mot Skills. 2009;108:717\u201320. https:\/\/doi.org\/10.2466\/PMS.108.3.717-720.","journal-title":"Percept Mot Skills"},{"key":"1326_CR48","doi-asserted-by":"publisher","unstructured":"de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, T\u00f3foli LF, Daldegan-Bueno D. Systematic review of psychometric instruments used in research with psychedelics. J Psychoactive Drugs. 2023:359\u201368. https:\/\/doi.org\/10.1080\/02791072.2022.2079108.","DOI":"10.1080\/02791072.2022.2079108"},{"key":"1326_CR49","doi-asserted-by":"publisher","unstructured":"Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. 2016;10. https:\/\/doi.org\/10.3389\/fnhum.2016.00269.","DOI":"10.3389\/fnhum.2016.00269"},{"key":"1326_CR50","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"key":"1326_CR51","doi-asserted-by":"publisher","unstructured":"Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:E245960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5960.","DOI":"10.1001\/jamanetworkopen.2024.5960"},{"key":"1326_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/02698811211064720","volume":"36","author":"JJ Rucker","year":"2022","unstructured":"Rucker JJ, Marwood L, Ajantaival RLJ, Bird C, Eriksson H, Harrison J, et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022;36:114\u201325. https:\/\/doi.org\/10.1177\/02698811211064720.","journal-title":"J Psychopharmacol"},{"key":"1326_CR53","doi-asserted-by":"publisher","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022:1100\u201317. https:\/\/doi.org\/10.1177\/02698811221116926.","DOI":"10.1177\/02698811221116926"},{"key":"1326_CR54","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/nejmoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311. https:\/\/doi.org\/10.1056\/nejmoa2032994.","journal-title":"N Engl J Med"},{"key":"1326_CR55","doi-asserted-by":"publisher","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, et al. Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023:61\u201376. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.011.","DOI":"10.1016\/j.euroneuro.2023.07.011"},{"key":"1326_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","volume":"123","author":"MW Johnson","year":"2012","unstructured":"Johnson MW, Andrew Sewell R, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012;123:132\u201340. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.10.029.","journal-title":"Drug Alcohol Depend"},{"key":"1326_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1027\/0269-8803\/A000040","volume":"24","author":"M Houa","year":"2010","unstructured":"Houa M, Tomberg C, No\u00ebl X. Alcohol and its impact on motor control. J Psychophysiol. 2010;24:259\u201363. https:\/\/doi.org\/10.1027\/0269-8803\/A000040.","journal-title":"J Psychophysiol"},{"key":"1326_CR58","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","volume":"7","author":"LV Kalia","year":"2008","unstructured":"Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7:742. https:\/\/doi.org\/10.1016\/S1474-4422(08)70165-0.","journal-title":"Lancet Neurol"},{"key":"1326_CR59","doi-asserted-by":"publisher","unstructured":"Hoffman PL, Rabe CS, Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol and the NMDA receptor. Alcohol. 1990;7:229\u201331. https:\/\/doi.org\/10.1016\/0741-8329(90)90010-A.","DOI":"10.1016\/0741-8329(90)90010-A"},{"key":"1326_CR60","doi-asserted-by":"publisher","unstructured":"Goetz T, Arslan A, Wisden W, Wulff P. GABAA receptors: structure and function in the basal ganglia. Prog Brain Res. 2007;160:21. https:\/\/doi.org\/10.1016\/S0079-6123(06)60003-4.","DOI":"10.1016\/S0079-6123(06)60003-4"},{"key":"1326_CR61","doi-asserted-by":"publisher","unstructured":"Kong LM, Zheng WB, Lian GP, Zhang HD. Acute effects of alcohol on the human brain: diffusion tensor imaging study. Am J Neuroradiol. 2012;33:928\u201334. https:\/\/doi.org\/10.3174\/AJNR.A2873.","DOI":"10.3174\/AJNR.A2873"},{"key":"1326_CR62","doi-asserted-by":"publisher","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10. https:\/\/doi.org\/10.1038\/s41598-020-59282-y.","DOI":"10.1038\/s41598-020-59282-y"},{"key":"1326_CR63","doi-asserted-by":"publisher","unstructured":"Lebedev A V., Kaelen M, L\u00f6vd\u00e9n M, Nilsson J, Feilding A, Nutt DJ, et al. LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp. 2016;37:3203\u201313. https:\/\/doi.org\/10.1002\/hbm.23234.","DOI":"10.1002\/hbm.23234"},{"key":"1326_CR64","doi-asserted-by":"publisher","unstructured":"Varley TF, Carhart-Harris R, Roseman L, Menon DK, Stamatakis EA. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. Neuroimage. 2020;220. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117049.","DOI":"10.1016\/j.neuroimage.2020.117049"},{"key":"1326_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","volume":"632","author":"JS Siegel","year":"2024","unstructured":"Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632:131\u20138. https:\/\/doi.org\/10.1038\/s41586-024-07624-5.","journal-title":"Nature"},{"key":"1326_CR66","doi-asserted-by":"publisher","unstructured":"Weiss F, Magnesa A, Gambini M, Gurrieri R, Annuzzi E, Elefante C, et al. Psychedelic-Induced neural plasticity: a comprehensive review and a discussion of clinical implications. Brain Sci; 2025. https:\/\/doi.org\/10.3390\/brainsci15020117","DOI":"10.3390\/brainsci15020117"},{"key":"1326_CR67","doi-asserted-by":"publisher","unstructured":"Bennett K, Diamond C, Hoeritzauer I, Gardiner P, McWhirter L, Carson A, et al. A practical review of functional neurological disorder (FND) for the general physician. Clin Med J Royal Coll Phys Lond. 2021:28\u201336. https:\/\/doi.org\/10.7861\/CLINMED.2020-0987.","DOI":"10.7861\/CLINMED.2020-0987"},{"key":"1326_CR68","doi-asserted-by":"crossref","unstructured":"Nielsen G, Stone J, Matthews A, Brown M, Sparkes C, Farmer R, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86:1113\u20139.","DOI":"10.1136\/jnnp-2014-309255"},{"key":"1326_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021. https:\/\/doi.org\/10.1080\/17512433.2021.1933434.","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01326-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:26Z","timestamp":1792010666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01326-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Austin Health, Austin Hospital, 145 Studley Rd, Heidelberg VIC 3084.","order":1,"name":"Ethics","label":"Trial Sponsor","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study sponsors and funders are not involved in study design; collection, management and analysis of data; and writing of the manuscript.","order":2,"name":"Ethics","label":"Role of Sponsors and Funders","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.A.K. is on the advisory board of Psychae Institute, a non-profit psychedelic research institute. R.A.K. has received grant funding from the Wellcome Trust, the Medical Research Council (U.K.), the National Health and Medical Research Council (Australia) and the Weary Dunlop Foundation for research on FND. R.A.K. receives royalties from Guildford Press for a book chapter on FND. J.R. has undertaken paid advisory boards for Clerkenwell Health (Past), Beckley PsyTech (Past), Delica Therapeutics (Past), and paid articles for Janssen. J.R. has received assistance for attendance at conferences from Compass Pathways (past) and Janssen. J.R. has been awarded grant funding (received and managed by King\u2019s College London) from Compass Pathways, Beckley PsyTech, Multidisciplinary Association for Psychedelic Studies, National Institute for Health Research, Wellcome Trust, and the Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust. O.C. has received funding from The Perception Restoration Foundation. C.B. has received funding from the Graham Burrows Travelling Scholarship, University of Melbourne, and honoraria for FND speaking engagements by Epworth Healthcare (Australia). G.N. is a founding member and on the board of directors of the Functional Neurological Disorder Society. He is on the medical advisory boards of the charities FND Hope U.K. and FND Action. He receives research funding from the National Institute for Health and Care Research (U.K.).","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this protocol has been awarded by the Austin Health Human Research Ethics Committee (HREC\/57390\/Austin-2020). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants for participation in this study.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Relevant data have been included in the Online Resources. Further details may be provided by the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.A.K. is the principal investigator and the senior researcher. C.B., O.C., G.N., D.B., S.I., S.B., S.Z., Z.A., G.O., D.M., J.R., M.B., O.D., A.B. and R.A.K. contributed to the development of the protocol. C.B., R.A.K. and Z.A. collected the data. C.B., S.B. and S.Z. developed the statistical analysis plan and conducted the analyses. All authors contributed to the interpretation of the findings. C.B. drafted the manuscript. A.B. and R.A.K. provided supervision. C.B. drafted the revisions in response to reviewer and editor comments. All authors approved the revisions and the final manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}